Healthcare Industry News: Hi·Art
News Release - January 20, 2009
TomoTherapy and Hitachi Medical Corporation Enter Into Distribution Agreement for JapanMADISON, Wis – Jan. 20, 2009 – (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ: TOMO) announced today that it has entered into an exclusive agreement with Hitachi Medical Corporation (HMC) to distribute the Hi·Art® cancer treatment system in Japan. Through the agreement, HMC will market, sell and service the innovative Hi·Art system, which facilitates highly precise, CT-guided radiation therapy for a wide range of clinical indications.
“Hitachi Medical Corporation is an ideal partner for us and for our valued customers, in one of our most important markets,” said TomoTherapy CEO Fred Robertson, M.D. “HMC’s robust national infrastructure and reputation for excellent technical and customer support will enhance our ability to service all hospitals in Japan that are currently using TomoTherapy technology. Additionally, this agreement represents a significant opportunity for us to reach new customers, and help advance the quality of cancer care across Japan, the second largest radiation therapy marketplace in the world.”
“The TomoTherapy Hi·Art system is being recognized as a novel radiation therapy system among Japanese customers. We believe that we can contribute to quality improvement of radiation therapy for cancer treatment in Japan through distribution and technical service of this system. And, we are going to strengthen our presence in the market by adding this system in our product portfolio as we become able to provide not only diagnostic solutions but also a treatment solution for customers in Japan,” said Hitachi Medical Vice President Michito Kinoshita.
About Hitachi Medical Corporation
Hitachi Medical Corporation is a full-line supplier of medical equipment, including but not limited to X-ray, CT, MRI, and Ultrasound systems, in Japan and global markets, and a member of Hitachi group companies.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.
Statements in this release regarding future business, plans, events, expectations, products and other similar matters, including but not limited to statements using the terms “will”, “can” and “believe” constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy’s filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy’s judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.